S)-2-tert-Butyl-6-[(4S,5R)-3,4-di­methyl-5-phenyloxazolidin-2-yl]phenol
[Figure 2]
[Figure 2]

disable zoom     view article
Figure 2 The enhanced Jmol figure of the title compound. This is the third in a series of three Jmol figures intended to illustrate some versatility of the program. See also: Campbell et al. (2010); Koyanagi et al. (2010). In this Jmol, all inter­active features are defined by text editing or hand writing the scripts. Most script artifacts are resolved by using this method and the orientation of the mol­ecule only depends upon the end-user's preference.





Highlight N3 substituent
Highlight C16 and substituent
Highlight C19 and substituent
Highlight none











This is the last in a series of three Jmol figures intended to illustrate some versatility of the program. In this Jmol, all interactive features are defined by text editing or hand writing the scripts. Most script artifacts are resolved by using this method and the orientation of the molecule only depends upon the end-user's preference.

Figure 2 The enhanced Jmol figure of the title compound. This is the third in a series of three Jmol figures intended to illustrate some versatility of the program. See also: Campbell et al. (2010); Koyanagi et al. (2010). In this Jmol, all inter­active features are defined by text editing or hand writing the scripts. Most script artifacts are resolved by using this method and the orientation of the mol­ecule only depends upon the end-user's preference.

Journal logo CRYSTALLOGRAPHIC
COMMUNICATIONS
ISSN: 2056-9890
Volume 66| Part 4| March 2010| Pages o902-o903
doi:10.1107/S1600536810009190
Follow Acta Cryst. E
Sign up for e-alerts
E-alerts
Follow Acta Cryst. on Twitter
Twitter
Follow us on facebook
Facebook
Sign up for RSS feeds
RSS